Simulations Plus Inc
NASDAQ:SLP
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
27.22
50.95
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Simulations Plus Inc
Revenue
Simulations Plus Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Simulations Plus Inc
NASDAQ:SLP
|
Revenue
$70m
|
CAGR 3-Years
15%
|
CAGR 5-Years
16%
|
CAGR 10-Years
20%
|
||
Veeva Systems Inc
NYSE:VEEV
|
Revenue
$2.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
21%
|
CAGR 10-Years
25%
|
||
Inspire Medical Systems Inc
NYSE:INSP
|
Revenue
$755.6m
|
CAGR 3-Years
55%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
||
Doximity Inc
NYSE:DOCS
|
Revenue
$475.4m
|
CAGR 3-Years
32%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
||
Omnicell Inc
NASDAQ:OMCL
|
Revenue
$1.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
10%
|
||
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Revenue
$791m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Simulations Plus Inc
Revenue Breakdown
Breakdown by Geography
Simulations Plus Inc
Total Revenue:
70m
USD
|
Americas:
50.5m
USD
|
EMEA:
14.1m
USD
|
Asia Pacific:
5.5m
USD
|
Breakdown by Segments
Simulations Plus Inc
Total Revenue:
70m
USD
|
Software:
41m
USD
|
Services:
29m
USD
|
Software Licenses:
956k
USD
|
Simulations Plus Inc
Glance View
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.
See Also
What is Simulations Plus Inc's Revenue?
Revenue
70m
USD
Based on the financial report for Aug 31, 2024, Simulations Plus Inc's Revenue amounts to 70m USD.
What is Simulations Plus Inc's Revenue growth rate?
Revenue CAGR 10Y
20%
Over the last year, the Revenue growth was 18%. The average annual Revenue growth rates for Simulations Plus Inc have been 15% over the past three years , 16% over the past five years , and 20% over the past ten years .